Anthrax (Bacillus anthracis)
Overview
Plain-Language Overview
Anthrax is a serious infection caused by the bacterium Bacillus anthracis that mainly affects the skin, lungs, and digestive system. It can enter the body through cuts in the skin, inhalation, or ingestion, leading to different forms of the disease. The most common form is cutaneous anthrax, which causes a painless sore with a black center. Inhalation anthrax affects the lungs and can cause severe breathing problems. Gastrointestinal anthrax affects the digestive tract and can cause severe abdominal pain and vomiting. The infection can spread quickly and become life-threatening if not treated promptly. Anthrax spores can survive in the environment for a long time, making it a concern for both natural outbreaks and bioterrorism.
Clinical Definition
Anthrax is an acute infectious disease caused by the gram-positive, spore-forming bacterium Bacillus anthracis. The core pathology involves the production of potent exotoxins—protective antigen, lethal factor, and edema factor—which disrupt host immune responses and cause tissue necrosis. Infection occurs through spore entry via cutaneous, inhalational, gastrointestinal, or injection routes, with cutaneous anthrax being the most common and inhalational anthrax the most lethal. The disease primarily affects the skin, respiratory tract, and gastrointestinal mucosa, leading to characteristic clinical syndromes such as a painless eschar, severe pneumonia, or hemorrhagic enteritis. The spores' ability to persist in the environment and resist harsh conditions contributes to its epidemiological significance. Anthrax is a major concern in both natural zoonotic transmission and as a potential bioterrorism agent due to its high mortality if untreated.
Inciting Event
Direct contact with spores through skin abrasions or mucous membranes initiates cutaneous anthrax.
Inhalation of aerosolized spores triggers inhalational anthrax with pulmonary involvement.
Ingestion of contaminated meat causes gastrointestinal anthrax.
Injection of contaminated drugs can cause injectional anthrax in intravenous drug users.
Latency Period
Cutaneous anthrax incubation typically ranges from 1 to 7 days after exposure.
Inhalational anthrax latency is usually 1 to 6 days but can be up to 60 days due to spore dormancy.
Gastrointestinal anthrax symptoms develop within 1 to 7 days post ingestion.
Injectional anthrax onset occurs within days to weeks after drug injection.
Diagnostic Delay
Nonspecific early symptoms such as fever and malaise mimic common infections, delaying diagnosis.
Lack of clinical suspicion in non-endemic areas leads to misdiagnosis.
Initial skin lesions resembling insect bites or cellulitis cause delayed recognition of cutaneous anthrax.
Limited access to specialized microbiologic testing for B. anthracis spores and toxin detection.
Clinical Presentation
Signs & Symptoms
Painless skin ulcer with a central black eschar and surrounding non-pitting edema in cutaneous anthrax.
Fever, malaise, and headache as systemic symptoms in all forms of anthrax.
Dyspnea, chest pain, and cough in inhalational anthrax due to hemorrhagic mediastinitis.
Severe gastrointestinal symptoms including nausea, vomiting, abdominal pain, and bloody diarrhea in gastrointestinal anthrax.
Rapid progression to septic shock in systemic anthrax infection.
History of Present Illness
Cutaneous anthrax begins with a painless papule that rapidly progresses to a vesicle and then a characteristic black eschar with surrounding edema.
Inhalational anthrax presents initially with nonspecific flu-like symptoms followed by severe respiratory distress and mediastinal widening on imaging.
Gastrointestinal anthrax manifests as severe abdominal pain, vomiting, and bloody diarrhea after ingestion of contaminated meat.
Injectional anthrax presents with severe soft tissue infection, extensive edema, and systemic toxicity without the classic eschar.
Past Medical History
Previous occupational exposure to animal products or travel to endemic areas increases risk.
History of skin trauma or wounds may predispose to cutaneous infection.
Immunocompromised states can worsen disease severity and complicate treatment.
Lack of prior anthrax vaccination in high-risk individuals is relevant.
Family History
[]
Physical Exam Findings
Painless ulcer with a black eschar surrounded by significant edema in cutaneous anthrax.
Mediastinal widening on chest exam in inhalational anthrax due to hemorrhagic lymphadenitis.
Tachycardia and hypotension indicating systemic toxicity in severe anthrax infection.
Pleural effusion signs such as decreased breath sounds in inhalational anthrax.
Lymphadenopathy near the site of infection in cutaneous anthrax.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of anthrax is established by identifying Bacillus anthracis through culture or polymerase chain reaction (PCR) from clinical specimens such as skin lesions, blood, or respiratory secretions. Characteristic clinical features include a painless black eschar in cutaneous anthrax or mediastinal widening on chest imaging in inhalational anthrax. Gram stain showing large gram-positive rods and the presence of capsule and spore-forming bacilli support the diagnosis. Serologic tests and immunohistochemistry can aid in confirmation. Rapid diagnosis is critical due to the disease's potential severity.
Pathophysiology
Key Mechanisms
Spore inhalation or cutaneous entry of Bacillus anthracis leads to germination and bacterial proliferation.
Anthrax toxin production includes protective antigen, edema factor, and lethal factor, which disrupt host immune responses and cause tissue necrosis.
Edema factor acts as an adenylate cyclase increasing intracellular cAMP, causing local edema and immune evasion.
Lethal factor is a protease that cleaves MAP kinase kinases, leading to macrophage apoptosis and systemic shock.
Capsule formation by B. anthracis inhibits phagocytosis and promotes bacterial survival in host tissues.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes serve as sites of bacterial replication and immune response initiation in systemic anthrax. |
Lungs are the primary organs affected in inhalational anthrax, leading to severe respiratory distress. | |
Skin is the organ involved in cutaneous anthrax, presenting with characteristic lesions. | |
| Tissues | Skin is the primary site of entry in cutaneous anthrax, where characteristic black eschar forms. |
Lymphatic tissue is involved as spores germinate and bacteria multiply, leading to lymphadenopathy. | |
Lung tissue is affected in inhalational anthrax causing hemorrhagic mediastinitis and respiratory failure. | |
| Cells | Macrophages phagocytose Bacillus anthracis spores and transport them to lymph nodes, initiating infection. |
Neutrophils are recruited to sites of infection to kill bacteria but may be overwhelmed by anthrax toxins. | |
Dendritic cells present anthrax antigens to activate adaptive immune responses. | |
| Chemical Mediators | Anthrax lethal toxin disrupts immune cell signaling causing cell death and immune evasion. |
Protective antigen facilitates entry of lethal and edema toxins into host cells, critical for virulence. | |
Edema toxin increases intracellular cAMP causing local edema and immune suppression. |
Treatments
Pharmacological Treatments
Ciprofloxacin
- Mechanism:
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Bacillus anthracis.
- Side effects:
Tendon rupture
Gastrointestinal upset
Photosensitivity
- Clinical role:
First-line
Doxycycline
- Mechanism:
Binds to the 30S ribosomal subunit, inhibiting protein synthesis in Bacillus anthracis.
- Side effects:
Photosensitivity
Gastrointestinal upset
Tooth discoloration in children
- Clinical role:
First-line
Raxibacumab
- Mechanism:
Monoclonal antibody that neutralizes anthrax toxin protective antigen, preventing toxin entry into host cells.
- Side effects:
Infusion reactions
Hypersensitivity reactions
- Clinical role:
Adjunctive
Anthrax vaccine (AVA)
- Mechanism:
Stimulates active immunity by inducing antibodies against anthrax protective antigen.
- Side effects:
Injection site reactions
Mild fever
Fatigue
- Clinical role:
Long-term control
Non-pharmacological Treatments
Surgical debridement of necrotic tissue in cutaneous anthrax to reduce bacterial load and toxin production.
Supportive care including fluid resuscitation and respiratory support in systemic anthrax cases.
Isolation precautions to prevent spread of spores in hospital settings.
Prevention
Pharmacological Prevention
Anthrax vaccine adsorbed (AVA) for high-risk populations such as military personnel and laboratory workers.
Post-exposure prophylaxis with ciprofloxacin or doxycycline for 60 days after suspected exposure to Bacillus anthracis spores.
Antitoxin therapies targeting anthrax toxins in combination with antibiotics during outbreaks.
Non-pharmacological Prevention
Avoidance of exposure to contaminated animal products and soil in endemic areas.
Use of personal protective equipment (PPE) including gloves and masks when handling potentially infected materials.
Proper disposal and incineration of animal carcasses to prevent spore dissemination.
Environmental decontamination of areas exposed to anthrax spores.
Education and training of at-risk workers on anthrax transmission and early symptom recognition.
Outcome & Complications
Complications
Septic shock due to systemic dissemination of Bacillus anthracis and toxin release.
Hemorrhagic mediastinitis causing respiratory failure in inhalational anthrax.
Meningitis secondary to hematogenous spread of anthrax.
Airway obstruction from massive edema in oropharyngeal or inhalational anthrax.
Death if untreated or in severe systemic cases.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Anthrax (Bacillus anthracis) versus Cutaneous Tularemia
Anthrax (Bacillus anthracis) | Cutaneous Tularemia |
|---|---|
Exposure to contaminated animal products or soil | Contact with rabbits or ticks in endemic areas |
Painless black eschar with extensive surrounding edema | Ulceroglandular lesion with granulomatous inflammation |
Positive culture or PCR for Bacillus anthracis | Positive serology or culture for Francisella tularensis |
Anthrax (Bacillus anthracis) versus Necrotizing Cellulitis (e.g., Staphylococcus aureus)
Anthrax (Bacillus anthracis) | Necrotizing Cellulitis (e.g., Staphylococcus aureus) |
|---|---|
Painless black eschar with marked non-pitting edema | Rapidly progressive painful erythema with systemic toxicity |
Edema with minimal neutrophilic infiltration and large gram-positive rods | Suppurative inflammation with neutrophilic infiltration |
Requires ciprofloxacin or doxycycline targeting spore-forming bacilli | Responds to beta-lactam antibiotics targeting gram-positive cocci |
Anthrax (Bacillus anthracis) versus Orf Virus Infection
Anthrax (Bacillus anthracis) | Orf Virus Infection |
|---|---|
Exposure to livestock or animal hides contaminated with spores | Direct contact with sheep or goats |
Painless ulcer with black eschar and extensive edema | Single or multiple nodular lesions with viral cytopathic changes |
Culture or PCR positive for Bacillus anthracis | PCR positive for parapoxvirus DNA |
Anthrax (Bacillus anthracis) versus Brown Recluse Spider Bite
Anthrax (Bacillus anthracis) | Brown Recluse Spider Bite |
|---|---|
Exposure to contaminated animal products or soil | History of spider exposure in endemic regions |
Painless black eschar with marked non-pitting edema | Painful necrotic ulcer with surrounding erythema and systemic symptoms |
Rapid onset of painless eschar with localized edema | Lesion evolves over days with possible systemic hemolysis |
Anthrax (Bacillus anthracis) versus Ecthyma Gangrenosum
Anthrax (Bacillus anthracis) | Ecthyma Gangrenosum |
|---|---|
Can occur in immunocompetent hosts after spore exposure | Occurs primarily in immunocompromised patients (e.g., neutropenia) |
Black eschar with extensive edema caused by Bacillus anthracis toxin | Necrotic skin lesions with vasculitis caused by Pseudomonas aeruginosa |
Positive culture or PCR for Bacillus anthracis | Positive culture for Pseudomonas aeruginosa |